Donna Reuter
Overview
Leveraging her experiences as a practitioner in the healthcare industry, Donna capably serves clients with her industry experience and her commitment to achieving client goals.
Career & Education
- Mitchell Hamline School of Law, J.D., 2019
- University of Minnesota, Pharm.D., 2011
- California State University, Fresno, B.A., Mass Communication and Journalism, 2006
- Minnesota
- District of Columbia
- U.S. District Court for the District of Minnesota
- U.S. Court of Appeals for the Eighth Circuit
Donna's Insights
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations
In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future.
Client Alert | 3 min read | 06.24.26
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
Client Alert | 5 min read | 04.07.26
Weight-Loss Drug Coverage Obligations: A Litigation and Regulatory Update
Insights
- |
07.01.24
Crowell & Moring’s Health Law Blog
Practices
Donna's Insights
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations
In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future.
Client Alert | 3 min read | 06.24.26
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
Client Alert | 5 min read | 04.07.26
Weight-Loss Drug Coverage Obligations: A Litigation and Regulatory Update




